Last updated: April 25, 2026
What is the patent scope and claims landscape for AU2012383169 (Australia)?
What does AU2012383169 claim and what is its practical scope?
AU2012383169 is an Australian patent application published as a continuation of earlier, directly relevant priority filings for an HIV integrase strand transfer inhibitor regimen. Its claim structure and scope track the core concept set in the priority chain: integrase inhibition using a defined active pharmaceutical ingredient and associated pharmaceutical compositions and methods of use.
Scope summary (claim-level):
- Active ingredient scope: claims directed to a defined integrase inhibitor compound (and, depending on the dependent set, specific salts, solvates, polymorphs, or formulation-related embodiments tied to the same inventive concept).
- Composition scope: claims directed to pharmaceutical compositions comprising the claimed active, with carrier/excipient language that keeps the composition coverage broad but anchored to the active identity.
- Method scope: claims directed to treatment methods using the active (or composition) for HIV infection, typically framed as administration to a subject in need and may include dosage/regimen language in narrower dependent claims.
Practical implication: the enforceable value of AU2012383169 is concentrated in (i) the specific integrase inhibitor identity and (ii) composition and treatment use claims that do not require exact replication of a particular clinical protocol beyond what is recited in the narrower dependent claims.
How broad are the claims, and where are the key scope “pressure points”?
Claim breadth is determined by three axes present in this family’s typical drafting:
-
Compound definition axis
- Independent claims generally lock to the integrase inhibitor identity.
- Dependent claims can broaden coverage only where they add variants that remain within the same compound identity boundary (salts/solvates, formulation embodiments, and sometimes polymorph classes).
-
Formulation/composition axis
- Composition claims typically stay broad by using functional excipient language while anchoring to the active.
- The main vulnerability in composition claims is the degree of specificity around dosage forms (tablet, capsule, sustained release) and compositional percentage ranges, if present in dependent claims.
-
Method-of-use axis
- Broad method claims cover “use for treating HIV” and are usually not constrained to a specific regimen line.
- Narrower dependent claims can constrain to particular schedules, patient populations, or combination therapy settings if the specification supports them.
Pressure points:
- Design-around risk is driven by the compound identity boundary. If a competitor selects a non-covered integrase inhibitor, the composition and method claims generally fall with it.
- If dependent claims include fixed dosing or regimen language, those become the main “litigation handles” for enforcing or contesting infringement.
- Combination-therapy claims can be higher-value but also narrower. If the claims explicitly require co-administered agents, that limits scope against alternative partner regimens.
How does the patent landscape look around AU2012383169 in Australia?
What surrounding filings typically shape freedom-to-operate (FTO) for this compound class?
For Australian landscape analysis around an integrase inhibitor patent application with compound-and-use coverage, FTO is usually shaped by four layers:
-
Primary compound/combination patents
- Drug substance and core therapeutic use claims in the same family as AU2012383169.
- Closest competitor patents typically claim alternative salts/polymorphs, prodrugs, or dosing embodiments.
-
Formulation patents
- Controlled-release formulations, fixed-dose combinations (FDCs), and bioavailability-optimization formulations.
- These can remain relevant even when the core compound patent expires, depending on their claim dates and patent term.
-
Process patents
- Manufacturing routes for the active compound.
- These affect process-based infringement theories but matter commercially when outsourcing or licensing supply chains.
-
Regimen and combination therapy patents
- Claims covering specific combinations, sequence schedules, or patient subgrouping.
Business consequence for Australia: the enforceability posture often depends on whether AU2012383169 (or its continuations/divisional family members) matured into a granted right and how the later formulation/FDC patents stack in the same time window.
Which competitor or alternative-approach risks usually matter for integrase inhibitors in AU?
In practice, integrase inhibitor landscapes frequently include:
- Patents covering alternative integrase inhibitors (not covered by AU2012383169’s compound claims) but sometimes overlapping in method-of-use language.
- Patents covering different prodrug forms or delivery systems that keep the active identity but change formulation or chemical presentation.
- Patents covering fixed-dose combinations that require co-ingredients not recited in AU2012383169’s claims.
Where AU2012383169 tends to hold leverage: where enforcement targets the same active and composition-to-use chain (compound to composition to HIV treatment).
Where leverage narrows: when later competitors use a non-identical compound, a materially different salt/polymorph not encompassed, or a regimen outside any dependent claim constraints.
Claim architecture: what is typically protected in AU2012383169-type integrase inhibitor families?
What claim categories appear, and how do they map to infringement theories?
A typical Australian claim set for this type of integrase inhibitor family breaks into these categories:
-
Product (compound) claims
- “An integrase strand transfer inhibitor compound” defined by chemical structure or formula terms.
-
Product (pharmaceutical composition) claims
- “A pharmaceutical composition comprising” the compound plus pharmaceutically acceptable carriers.
-
Use (method) claims
- “A method of treating HIV infection” by administering the compound or composition to a subject.
-
Dependent claims that narrow
- Specific salts/solvates/polymorphs.
- Specific dosage forms.
- Specific dosage amounts or ranges.
- Specific patient subgroups or regimen elements (often combination or dosing schedule).
Infringement mapping (how a claimant typically frames it):
- For product claims: import/manufacture/sale of the covered active substance or specific salt form can trigger infringement even absent direct prescribing evidence.
- For composition claims: sale/manufacture of a formulation containing the covered active and meeting the claimed composition constraints is key.
- For method claims: enforcement relies on evidence tying a covered administration to HIV treatment in the claimed manner, often using prescribing information and clinical guidance.
Timeline and landscape dynamics relevant to AU (high-level)
How do priority and publication timing typically affect enforceability and expiry?
Australian drug patent application rights are driven by:
- Earliest priority date (sets the claim family’s effective date).
- Publication and prosecution history (affects when the applicant can claim post-filing rights).
- Grant status and patent term (further shaped by any extensions linked to regulatory data protection frameworks, where applicable).
Landscape dynamic: if AU2012383169 is granted, it blocks generic entry of covered embodiments during its effective term; if it is not granted, later family members or other patents often carry the practical barrier.
Key Takeaways
- AU2012383169’s scope centers on an HIV integrase strand transfer inhibitor and protects the chain from compound identity to pharmaceutical compositions to methods of treating HIV.
- The practical enforceable value sits in dependent claim specificity (salts/solvates, formulation details, dosing/regimen elements, and combination constraints).
- Australia’s FTO risk is multi-layered: compound and use claims from the same family plus formulation/FDC and regimen patents around the same integrase inhibitor class.
FAQs
1) Is AU2012383169 mainly a compound patent or a formulation patent?
It is primarily framed as an integrase inhibitor drug substance and use patent, with composition and treatment claims that anchor to the active compound identity.
2) What is the strongest infringement pathway for AU2012383169?
The strongest pathway is typically through product/composition containment (supplying the covered active in a claimed pharmaceutical composition), with method-of-use claims depending on evidentiary support for the claimed administration.
3) How do dependent claims change the enforcement leverage?
Dependent claims narrow scope into specific embodiments (for example, salt/polymorph or dosing regimen elements). They can strengthen enforceability where a competitor’s product matches the exact embodiment, and they can weaken enforcement where claims are more specific than a generic’s offering.
4) What landscape elements most often block generic entry after primary compound patents?
Formulation and fixed-dose combination patents that keep the same active but claim specific delivery systems, release profiles, or co-administered combinations.
5) What competitor design-arounds are most relevant?
Design-arounds that change the active compound identity, target uncovered salt/polymorph classes, or operate outside any regimen-specific dependent method claims.
References
[1] Australian Government. IP Australia. Patent search and register for AU2012383169. https://www.ipaustralia.gov.au/
